- Prime Radiant Fund SLP SICAV-RAIF has invested $50 million in Cellares’ Series D financing, bringing the total raised in the round to $327 million.
- The funding will support Cellares’ global Smart Factory expansion, including a cell therapy manufacturing facility under construction in Leiden, the Netherlands, expected to be GMP-ready in 2027.
Cellares has received a $50 million growth equity investment from Prime Radiant Fund SLP SICAV-RAIF, a fund advised by Prime Radiant Partners, extending its Series D financing round to $327 million. Prime Radiant joins a group of investors that includes ARK Invest, investment funds managed by BlackRock, Eclipse, T. Rowe Price Investment Management, Inc., Duquesne Family Office, Baillie Gifford, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors.
The funding will support the next phase of the company’s global Smart Factory buildout. A manufacturing facility under construction in Leiden, the Netherlands, is designed to provide drug sponsors with the same automated cell therapy manufacturing infrastructure available in the United States. The facility is expected to be GMP-ready in 2027.
According to the company, the expansion is intended to support a global cell therapy manufacturing network across major markets. Prime Radiant said its experience in European healthcare and pharma services will support Cellares’ growth in Europe as demand for automated manufacturing increases across the region.
“Prime Radiant’s operational depth in pharma services across continental Europe makes them a strategic partner as we expand our manufacturing presence in Europe.”
Fabian Gerlinghaus, Co-Founder and CEO of Cellares
The Series D extension comes as Cellares expands its manufacturing platform across CAR T, TCR-T, and progenitor T cell therapy programs. The company said drug sponsors including Bristol Myers Squibb, Cabaletta Bio, TScan Therapeutics, and ProTgen are using its Cell Shuttle® platform across development and commercial manufacturing stages. Cellares also cited a $380 million global manufacturing agreement with Bristol Myers Squibb and a 10-year commercial supply agreement with Cabaletta Bio signed in April 2026 following the delivery of GMP cell therapy doses produced on the platform.
